AbbVie Acquires Celsius Therapeutics

Celsius Therapeutics, a biotechnology start-up, was purchased by AbbVie for $250 million in cash. Celsius is committed to creating novel therapies for inflammatory illnesses. With the addition of a possible game-changing medicine to its pipeline, AbbVie’s presence in the management of inflammatory illnesses is expanded by this calculated move.

According to the purchase conditions, AbbVie will acquire all of Celsius’s outstanding equity, with the usual modifications.

The experimental antibody CEL383, created by Celsius to treat inflammatory bowel disease (IBD), is now available to AbbVie.

Preclinical studies have demonstrated the potential of CEL383, as it was able to efficiently suppress TREM1 signalling. Critical inflammatory mediator levels were lowered as a result of this restriction.

AbbVie immunology clinical development global head and vice-president Kori Wallace commented: “Given the potential relevance of TREM1 as a key driver of inflammation and pathology in IBD and other conditions, we are eager to advance the development of CEL383 with a goal of helping more patients with IBD achieve remission.”